Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems

Atorvastatin (ATV) is primarily metabolized by CYP3A in the liver to form two active hydroxy metabolites. Therefore, the sequential transport system governed by hepatic uptake and efflux transporters is important for the drug disposition and metabolism. Here, we assessed the interaction of ATV with hepatic uptake transporter organic anion transporting polypeptide (Oatp) and efflux transporter multidrug resistance associated protein 2 (MRP2/Mrp2) in vitro and ex situ using the isolated perfused rat liver (IPRL). Rifampicin (RIF) was chosen as an inhibitor for Oatp in both uptake and IPRL studies. Its inhibitory effects on MRP2 and metabolism were also tested using MRP2-overexpressing cells and rat microsomes, respectively. Our results indicate that RIF effectively inhibits the Oatp-mediated uptake of ATV and its metabolites. Inhibition on MRP2-mediated efflux of ATV was also observed at a high RIF concentration. Compared with ATV alone in the IPRL, the area under the curve(s) (AUC) of ATV was significantly increased by RIF, whereas the AUC of both metabolites were also increased in a concentration-dependent manner. However, the extent of metabolism was significantly reduced, as reflected by the reduced amounts of metabolites detected in RIF-treated livers. In conclusion, inhibition of Oatp-mediated uptake seems to be the major determinant for interaction between ATV and RIF. Metabolites of ATV were subject to Oatp-mediated uptake as well, suggesting that they undergo a similar disposition pathway as the parent drug. These data emphasize the relevance of uptake transporter as being one of the major players in hepatic drug elimination, even for substrates that undergo metabolism.

[1]  Michael Zschiesche,et al.  Induction of P‐glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction , 2000, Clinical pharmacology and therapeutics.

[2]  H. Yawo,et al.  Pravastatin, an HMG-CoA Reductase Inhibitor, Is Transported by Rat Organic Anion Transporting Polypeptide, oatp2 , 1999, Pharmaceutical Research.

[3]  Paul D. Martin,et al.  Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine , 2004, Clinical pharmacology and therapeutics.

[4]  M. Fromm,et al.  The effect of rifampin treatment on intestinal expression of human MRP transporters. , 2000, The American journal of pathology.

[5]  M. Clozel,et al.  Inhibition of Organic Anion Transporting Polypeptide-Mediated Hepatic Uptake Is the Major Determinant in the Pharmacokinetic Interaction between Bosentan and Cyclosporin A in the Rat , 2004, Journal of Pharmacology and Experimental Therapeutics.

[6]  P. Meier,et al.  Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2 , 2000, Hepatology.

[7]  B. H. Stewart,et al.  Atorvastatin Transport in the Caco-2 Cell Model: Contributions of P-Glycoprotein and the Proton-Monocarboxylic Acid Co-Transporter , 2000, Pharmaceutical Research.

[8]  P. Neuvonen,et al.  Effect of itraconazole on the pharmacokinetics of atorvastatin , 1998, Clinical pharmacology and therapeutics.

[9]  L. Alexandre,et al.  D2-Like Receptors Mediate the Expulsion Phase of Ejaculation Elicited by 8-Hydroxy-2-(di-N-propylamino)tetralin in Rats , 2006, Journal of Pharmacology and Experimental Therapeutics.

[10]  K. Brøsen,et al.  Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide , 2004, European Journal of Clinical Pharmacology.

[11]  M Rowland,et al.  Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine , 1995, Clinical pharmacology and therapeutics.

[12]  K. Higaki,et al.  Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  T. Abe,et al.  Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* , 2002, The Journal of Biological Chemistry.

[14]  T. Abe,et al.  Comparative Inhibitory Effects of Different Compounds on Rat Oatp1 (Slc21a1)- and Oatp2 (Slc21a5)-Mediated Transport , 2002, Pharmaceutical Research.

[15]  U. Christians,et al.  CYP3A4-Transfected Caco-2 Cells as a Tool for Understanding Biochemical Absorption Barriers: Studies with Sirolimus and Midazolam , 2004, Journal of Pharmacology and Experimental Therapeutics.

[16]  Yuichi Sugiyama,et al.  Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A , 2003, Journal of Pharmacology and Experimental Therapeutics.

[17]  Julia Qiu,et al.  Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin , 2004, Pharmaceutical Research.

[18]  Terry A Jacobson,et al.  Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. , 2004, The American journal of cardiology.

[19]  Leslie Z Benet,et al.  Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[20]  P. Kollman,et al.  Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[21]  D. Keppler,et al.  Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. , 2001, Molecular pharmacology.

[22]  Kaoru Kobayashi,et al.  Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells , 2005, Pharmacogenetics and genomics.

[23]  H. Yawo,et al.  Molecular characterization and functional regulation of a novel rat liver-specific organic anion transporter rlst-1. , 1999, Gastroenterology.

[24]  S. Vavricka,et al.  Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver , 2002, Hepatology.

[25]  Y. Sugiyama,et al.  Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. , 2004, Molecular pharmacology.

[26]  I. Pastan,et al.  A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Leslie Z. Benet,et al.  Ex Situ Inhibition of Hepatic Uptake and Efflux Significantly Changes Metabolism: Hepatic Enzyme-Transporter Interplay , 2004, Journal of Pharmacology and Experimental Therapeutics.

[28]  H. Lennernäs.  Clinical Pharmacokinetics of Atorvastatin , 2003, Clinical pharmacokinetics.

[29]  R. Kim,et al.  Human Organic Anion Transporting Polypeptide-C (SLC21A6) Is a Major Determinant of Rifampin-Mediated Pregnane X Receptor Activation , 2003, Journal of Pharmacology and Experimental Therapeutics.

[30]  V. Sasseville,et al.  A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2) , 1999, The Journal of Biological Chemistry.

[31]  D. Sprecher,et al.  Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[32]  L. Benet,et al.  Comparison of Furosemide and Vinblastine Secretion from Cell Lines Overexpressing Multidrug Resistance Protein (P-Glycoprotein) and Multidrug Resistance-Associated Proteins (MRP1 and MRP2) , 2002, Pharmacology.

[33]  P. Neuvonen,et al.  Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites , 2005, Clinical pharmacology and therapeutics.

[34]  D. Keppler,et al.  Introduction: Transport across the hepatocyte canalicular membrane , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  P. Meier,et al.  Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver , 1997, Hepatology.

[36]  O. Fardel,et al.  Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. , 1995, Biochemical pharmacology.

[37]  K. Chiba,et al.  A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. , 2004, Drug metabolism and pharmacokinetics.

[38]  G R Wilkinson,et al.  OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[39]  P. Meier,et al.  Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3 , 2001, Pflügers Archiv.

[40]  B. Roth,et al.  Metabolism and excretion of atorvastatin in rats and dogs. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[41]  L. Benet,et al.  Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction , 1992, Clinical pharmacology and therapeutics.

[42]  J. Xu,et al.  DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1 , 2005, Drug Metabolism and Disposition.

[43]  L. Benet,et al.  Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[44]  P. Neuvonen,et al.  Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. , 2005, Basic & clinical pharmacology & toxicology.

[45]  De-Pei Li,et al.  Presynaptic α1 Adrenergic Receptors Differentially Regulate Synaptic Glutamate and GABA Release to Hypothalamic Presympathetic Neurons , 2006, Journal of Pharmacology and Experimental Therapeutics.

[46]  M. Kool,et al.  Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.

[47]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[48]  Hong Sun,et al.  EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN , 2004, Drug Metabolism and Disposition.